LL-37 is a human host-defense peptide with immune-signaling research and a venous-ulcer trial that found no significant benefit across its full study population.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Human cathelicidin host-defense peptide
LL-37 is a 37-residue peptide produced by cleavage of the human cathelicidin precursor hCAP18. Neutrophils and epithelial cells contribute to its biological context. Its endogenous role in host defense is distinct from the question of whether an externally supplied formulation improves a particular disease outcome.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Cell experiments show that LL-37 can recruit immune cells and stimulate calcium signaling through the receptor historically called FPRL1. This complements its antimicrobial research background. A response involving immune-cell recruitment should not be simplified into a universal anti-inflammatory or immune-enhancing effect.
Experiments with human monocytes, neutrophils, T cells, and receptor-expressing cells examined chemotaxis and calcium responses. These results support a signaling role in host defense, while remaining laboratory observations rather than demonstrations of benefit in patients. [1]
A randomized, blinded phase IIb study evaluated a topical LL-37 formulation alongside compression therapy in 148 participants. The efficacy analysis found no significant healing improvement versus placebo across the full study population. [2]
A post hoc analysis of the same trial reported favorable findings among participants with larger ulcers. Because that analysis followed the overall evaluation, it generates a hypothesis requiring a suitably designed confirmatory trial rather than establishing an effective subgroup treatment. [2]
Study topics describe the cited models, not established benefits of this catalog material.
The clinical literature cited here concerns a particular topical formulation and wound population. It does not establish systemic benefits, general infection treatment, or improved immune function. Biological activity of the naturally occurring peptide and efficacy of a manufactured intervention are separate research questions.
The exploratory subgroup signal should remain secondary to the trial's overall negative result. Findings cannot be transferred across administration routes, disease settings, or formulations. Neither the immune-cell experiments nor the clinical study establishes equivalence to WYZ Labs materials or resolves long-term safety in other contexts.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Title abbreviated. Human leukocyte and receptor-transfected-cell chemotaxis experiments.
148 participants; no significant overall healing benefit, with exploratory post hoc subgroup findings.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
